Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 10/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3766091 | 0.86 | FAAH (0.69) | FAAHSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL3771939 | 0.86 | FAAH (0.63) | FAAHSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL3769563 | 0.85 | FAAH (0.60) | FAAHSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL3764618 | 0.84 | FAAH (0.63) | FAAHSMN1; SMN2NPC1RAB9A | |
| SCHEMBL3771924 | 0.83 | FAAH (0.62) | FAAHSMN1; SMN2MAPTMAPK1HTT | |
| SCHEMBL3778304 | 0.80 | FAAH (0.61) | FAAHSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL3774639 | 0.79 | FAAH (0.67) | FAAHSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL3765881 | 0.79 | FAAH (0.54) | FAAHSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL3760999 | 0.78 | RAB9A (0.66) | FAAHSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL3274880 | 0.78 | FAAH (0.57) | FAAHMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | FAAH 1/4885SMN1; SMN2 2454/4885NPC1 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.